Mirati Therapeutics, Inc. (MRTX) has a consensus analyst rating of Hold, based on 31 analysts covering the stock. Of those, 14 recommend buying, 17 recommend holding, and 0 recommend selling.
The analyst consensus price target for MRTX is $102.10, representing a +73.9% upside from the current price of $58.7. Price targets range from a low of $53.00 to a high of $247.00.
